Results 11 to 20 of about 20,522 (204)

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations

open access: yesPharmaceutics, 2022
Two active pharmaceutical ingredients (APIs) with limited solubility, simvastatin and ezetimibe, prepared as a drug-drug solid dispersion (SD) was evaluated for physicochemical, microstructural, and aqueous dissolution properties.
Agata Górniak   +4 more
doaj   +2 more sources

Ezetimibe: An Unusual Suspect in Angioedema

open access: yesCase Reports in Medicine, 2020
We describe a case of new onset angioedema likely due to Ezetimibe therapy in an elderly patient with a prior history of drug-induced bradykinin reactions who had been on the medication for multiple years.
Tiffany Lu, Tarundeep Grewal
doaj   +2 more sources

Species Differences in Ezetimibe Glucuronidation

open access: yesMetabolites
Background: Peclinical and clinical studies have revealed that ezetimibe, an approved cholesterol-absorption inhibitor, is rapidly and extensively metabolized to a more potent metabolite, ezetimibe glucuronide.
Shalom Emmanuel   +5 more
doaj   +2 more sources

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects

open access: yesDrug Design, Development and Therapy, 2017
Chang Hee Kim,1 Hyungmi An,2 Sung Hye Kim,3 Dongseong Shin4 1Department of Urology, Gachon University Gil Medical Center, Incheon, 2Department of Statistics, Seoul National University, Seoul, 3Clinical Development, Navipharm Co., Ltd., Suwon ...
Kim CH, An H, Kim SH, Shin D
doaj   +1 more source

Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe

open access: yesClinical and Translational Science
Ezetimibe undergoes glucuronidation that results in the active metabolite ezetimibe phenoxy‐glucuronide (ezetimibe‐glucuronide). This phase‐II metabolite was shown to interact with the clinically relevant hepatic transporter organic anion transporting ...
Jonny Kinzi   +4 more
doaj   +2 more sources

Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway

open access: yesBiomedicines
Background: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating ...
Charmy Twala   +4 more
doaj   +2 more sources

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia [PDF]

open access: yesVascular Health and Risk Management, 2010
Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse21Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, AustraliaAbstract: High-dose potent statin therapy in ...
Ian Hamilton-Craig   +3 more
doaj   +2 more sources

Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis. [PDF]

open access: yesEndocrinol Diabetes Metab
A network meta‐analysis of 43 randomized trials showed that oral combination therapies, particularly obicetrapib plus ezetimibe and bempedoic acid plus ezetimibe, achieved the greatest LDL‐C reduction with reassuring safety profiles, supporting their use as effective oral alternatives for patients with dyslipidaemia. ABSTRACT Introduction Dyslipidaemia
Hodrob T   +6 more
europepmc   +2 more sources

Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway

open access: yesHeliyon, 2023
Cholesterol levels were strongly associated with tumor progression and metastasis. Targeted cholesterol metabolism has broad prospects in tumor treatment.
Qinyu He   +8 more
doaj   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

open access: yes, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy